Paper36933320
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A and 2 others. ESMO Open, 2023. Cited by 136 papers, by iCite.
Cite this record
ConductScience Library. Anti-TIGIT therapies for solid tumors: a systematic review. Papers, record 36933320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36933320
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Antibodies, Monoclonal | |
| Nivolumab | |
| Receptors, Immunologic |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30733837 | Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. | Dis Markers | 2019 | https://conductscience.org/library/papers/30733837 | PubMed |
| 2 | 21416464 | Vstm3 is a member of the CD28 family and an important modulator of T-cell function. | Eur J Immunol | 2011 | https://conductscience.org/library/papers/21416464 | PubMed |
| 3 | 31655605 | The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31655605 | PubMed |
| 4 | 27718847 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718847 | PubMed |
| 5 | 27546235 | Sex differences in immune responses. | Nat Rev Immunol | 2016 | https://conductscience.org/library/papers/27546235 | PubMed |
| 6 | 26413872 | TIGIT predominantly regulates the immune response via regulatory T cells. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26413872 | PubMed |
| 7 | 34367161 | TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. | Front Immunol | 2021 | https://conductscience.org/library/papers/34367161 | PubMed |
| 8 | 28102259 | Elements of cancer immunity and the cancer-immune set point. | Nature | 2017 | https://conductscience.org/library/papers/28102259 | PubMed |
| 9 | 31954274 | Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). | Int Immunopharmacol | 2020 | https://conductscience.org/library/papers/31954274 | PubMed |
| 10 | 32265229 | CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/32265229 | PubMed |
| 11 | 16034094 | CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. | J Immunol | 2005 | https://conductscience.org/library/papers/16034094 | PubMed |
| 12 | 38206370 | Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. | Cancer Chemother Pharmacol | 2024 | https://conductscience.org/library/papers/38206370 | PubMed |
| 13 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 14 | 36289396 | Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. | Sci Rep | 2022 | https://conductscience.org/library/papers/36289396 | PubMed |
| 15 | 35263569 | Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. | Immunity | 2022 | https://conductscience.org/library/papers/35263569 | PubMed |
| 16 | 35522941 | PD-L1/TIGIT bispecific antibody showed survival advantage in animal model. | Clin Transl Med | 2022 | https://conductscience.org/library/papers/35522941 | PubMed |
| 17 | 35273608 | An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. | Front Immunol | 2022 | https://conductscience.org/library/papers/35273608 | PubMed |
| 18 | 19043418 | Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Nat Immunol | 2009 | https://conductscience.org/library/papers/19043418 | PubMed |
| 19 | 34897277 | T cell receptor (TCR) signaling in health and disease. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34897277 | PubMed |
| 20 | 34800678 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. | Ann Oncol | 2022 | https://conductscience.org/library/papers/34800678 | PubMed |
Cited by101
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42968166 | Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact. | J Transl Med | 2026 | https://conductscience.org/library/papers/42968166 | PubMed |
| 42811017 | Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. | Nat Commun | 2026 | https://conductscience.org/library/papers/42811017 | PubMed |
| 42769891 | Resistance Mechanisms in Immunotherapy-Radiotherapy/Chemotherapy Combinations in Locally Advanced Head & Neck Squamous Cell Carcinoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769891 | PubMed |
| 42768460 | Beyond PD-1: Expanding the Landscape of Immune Checkpoint Targets in Cancer Therapy. | Curr Drug Targets | 2026 | https://conductscience.org/library/papers/42768460 | PubMed |
| 42722716 | αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells. | Cell Mol Immunol | 2026 | https://conductscience.org/library/papers/42722716 | PubMed |
| 42654087 | The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654087 | PubMed |
| 42574065 | Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42574065 | PubMed |
| 42507968 | SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/42507968 | PubMed |
| 42443153 | Restoring the CD226 in CD8+T cells overcomes TIGIT-refractory immunity in HER2+ breast cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42443153 | PubMed |
| 42353092 | Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353092 | PubMed |
| 42352533 | The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352533 | PubMed |
| 42180871 | Integrated single-cell and bulk RNA sequencing reveals novel biomarkers of invasive adenocarcinoma subtypes in lung adenocarcinoma. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180871 | PubMed |
| 42161400 | CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42161400 | PubMed |
| 42148118 | Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth. | Front Immunol | 2026 | https://conductscience.org/library/papers/42148118 | PubMed |
| 42097144 | HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42097144 | PubMed |
| 41883115 | Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies. | J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41883115 | PubMed |
| 41876785 | Cellular landscape and diagnostic value of TROP2 in cerebrospinal fluid of lung adenocarcinoma leptomeningeal metastases. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/41876785 | PubMed |
| 41857153 | Prognostic impact of sarcopenia and blood biomarkers in advanced non-small cell lung cancer on first-line immune checkpoint inhibitors. | Sci Rep | 2026 | https://conductscience.org/library/papers/41857153 | PubMed |
| 41842954 | Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy. | Inflamm Res | 2026 | https://conductscience.org/library/papers/41842954 | PubMed |
| 41737188 | Proliferative double-negative T (DNT)-cell responses to PD-1 blockade therapy were positively correlated with good clinical outcomes in non-small cell lung cancer patients. | Pak J Med Sci | 2026 | https://conductscience.org/library/papers/41737188 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36933320
GET https://conductscience.org/api/papers/v1/36933320/references?page=2